{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:10:48Z","timestamp":1789049448243,"version":"build-2803163510"},"reference-count":23,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Inflammatory labyrinthitis is defined as a fluctuant vestibulo-cochlear syndrome associated with an impairment of the blood-labyrinthine barrier (BLB) on delayed FLAIR MRI sequences. Systemic and intratympanic corticosteroids are the gold standard treatment but their effect is frequently insufficient. The objective is here to determine whether infliximab could be of value in the treatment of bilateral inflammatory labyrinthitis. A retrospective monocentric study was conducted between January 2013 and December 2021. All patients included in the study were affected with a bilateral vestibulo-cochlear syndrome associated with bilateral blood-labyrinthine barrier impairment. Patients were administered infliximab at the dose of 5 mg\/kg every 6 weeks for 6 months. Audiometry, MRI with delayed FLAIR sequences on the labyrinth, and corticosteroid doses still required were assessed both before and after treatment with infliximab was completed. Pure-tone average (PTA) was the primary outcome. The secondary outcomes were the speech recognition threshold (SRT), the Dizziness Handicap Inventory (DHI) score, and the corticosteroid (CS) dose. A total of nine patients including five men and four women were enrolled in the study. Thirteen ears were analyzed. After a 6-month period of treatment, the mean PTA (54 \u00b1 24 db versus 66 \u00b1 22 db; p = 0.027), SRT (54 \u00b1 37 db versus 66 \u00b1 32 db; p = 0.041) and DHI score (27 \u00b1 15 versus 9 \u00b1 2; p = 0.032) significantly improved. After the 6-month treatment period, the mean CS dose decreased from 38 \u00b1 33 to 6 \u00b1 5 mg\/day (p = 0.003). We conclude that infliximab substantially improves the vestibulo-cochlear function in patients with bilateral inflammatory labyrinthitis and could be of value in corticosteroid-dependent cases.<\/jats:p>","DOI":"10.3390\/jcm12134350","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T01:15:47Z","timestamp":1688001347000},"page":"4350","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Infliximab for the Treatment of Inflammatory Labyrinthitis: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"12","author":[{"given":"Cassandre","family":"Djian","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2014H\u00f4pitaux de Paris, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Champion","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2014H\u00f4pitaux de Paris, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2014H\u00f4pitaux de Paris, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Drouet","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saint Joseph Hospital, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-8721","authenticated-orcid":false,"given":"Blanca","family":"Amador Borrero","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2014H\u00f4pitaux de Paris, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Depond","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2014H\u00f4pitaux de Paris, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Mouly","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2014H\u00f4pitaux de Paris, 75010 Paris, France"},{"name":"Facult\u00e9 de M\u00e9decine, Paris Cit\u00e9 University, 75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Jourdaine","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2014H\u00f4pitaux de Paris, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Herman","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2014H\u00f4pitaux de Paris, 75010 Paris, France"},{"name":"Facult\u00e9 de M\u00e9decine, Paris Cit\u00e9 University, 75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Eliezer","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2014H\u00f4pitaux de Paris, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hautefort","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2014H\u00f4pitaux de Paris, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"S\u00e8ne","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2014H\u00f4pitaux de Paris, 75010 Paris, France"},{"name":"Facult\u00e9 de M\u00e9decine, Paris Cit\u00e9 University, 75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/00005537-199611000-00007","article-title":"Histopathology of idiopathic chronic recurrent vertigo","volume":"106","author":"Ishiyama","year":"1996","journal-title":"Laryngoscope"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/lio2.508","article-title":"Autoimmune inner ear disease: A systematic review of management","volume":"5","author":"Breslin","year":"2020","journal-title":"Laryngoscope Investig. Otolaryngol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5072582","DOI":"10.1155\/2018\/5072582","article-title":"Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment","volume":"2018","author":"Girasoli","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoto.2020.0047","article-title":"Intratympanic vs Systemic Corticosteroids in First-line Treatment of Idiopathic Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis","volume":"146","author":"Mirian","year":"2020","journal-title":"JAMA Otolaryngol.-Head Neck Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13052-016-0291-2","article-title":"Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Beh\u00e7et disease responding to adalimumab: A case report","volume":"42","author":"Marsili","year":"2016","journal-title":"Ital. J. Pediatr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1288\/00005537-199005000-00015","article-title":"Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss","volume":"100","author":"Harris","year":"1990","journal-title":"Laryngoscope"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1007\/s00330-018-5825-0","article-title":"Detection of intralabyrinthine abnormalities using post-contrast delayed 3D-FLAIR MRI sequences in patients with acute vestibular syndrome","volume":"29","author":"Eliezer","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: A systematic literature review and network meta-analysis","volume":"6","author":"Perry","year":"2020","journal-title":"RMD Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ibd\/izx072","article-title":"Infliximab for Crohn\u2019s Disease: More Than 13 Years of Real-world Experience","volume":"24","author":"Lichtenstein","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/01.mao.0000185082.28598.87","article-title":"Etanercept treatment for autoimmune inner ear disease: Results of a pilot placebo-controlled study","volume":"26","author":"Cohen","year":"2005","journal-title":"Otol. Neurotol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/art.21179","article-title":"Etanercept therapy for immune-mediated cochleovestibular disorders: A multi-center, open-label, pilot study","volume":"53","author":"Matteson","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00129492-200109000-00010","article-title":"Etanercept therapy for immune-mediated cochleovestibular disorders: Preliminary results in a pilot study","volume":"22","author":"Rahman","year":"2001","journal-title":"Otol. Neurotol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/kes346","article-title":"Severe deafness associated with Crohn\u2019s disease and spondylarthropathy: Successful treatment with anti-TNF","volume":"52","author":"Jachiet","year":"2013","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_14","first-page":"e228","article-title":"Successful Treatment of Recurrent Sensorineural Hearing Loss in Ankylosing Spondylitis Using Infliximab and Methotrexate","volume":"26","author":"Niwano","year":"2020","journal-title":"J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1017\/S002221511300217X","article-title":"Infliximab for autoimmune inner ear disease: Case report and literature review","volume":"127","author":"Heywood","year":"2013","journal-title":"J. Laryngol. Otol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/MAO.0000000000003743","article-title":"Disease-Modifying Antirheumatic Drugs in the Treatment of Autoimmune Inner Ear Disease: A Systematic Review and Meta-Analysis of Auditory and Vestibular Outcomes","volume":"44","author":"Gordis","year":"2023","journal-title":"Otol. Neurotol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00129492-200301000-00012","article-title":"Blockage of Immune-Mediated Inner Ear Damage by Etanercept","volume":"24","author":"Wang","year":"2003","journal-title":"Otol. Neurotol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/archotol.1990.01870040046011","article-title":"The development of the Dizziness Handicap Inventory","volume":"116","author":"Jacobson","year":"1990","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1017\/S0022215106002593","article-title":"Etanercept, a tumour necrosis factor alpha receptor antagonist, and methotrexate in acute sensorineural hearing loss","volume":"120","author":"Street","year":"2006","journal-title":"J. Laryngol. Otol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.autrev.2017.10.005","article-title":"Cogan syndrome: Characteristics, outcome and treatment in a French nationwide retrospective study and literature review","volume":"16","author":"Durtette","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1517\/14740338.7.5.617","article-title":"Long-term treatment with infliximab in inflammatory bowel disease: Safety and tolerability issues","volume":"7","author":"Caviglia","year":"2008","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.14309\/ajg.0000000000001842","article-title":"Efficacy and Safety of Infliximab Retreatment in Crohn\u2019s Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID","volume":"117","author":"Boschetti","year":"2022","journal-title":"Am. J. Gastroenterol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/13\/4350\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:02:36Z","timestamp":1760126556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/13\/4350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":23,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["jcm12134350"],"URL":"https:\/\/doi.org\/10.3390\/jcm12134350","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,28]]}}}